X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Natco Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs NATCO PHARMA - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA NATCO PHARMA ASTRAZENECA PHARMA/
NATCO PHARMA
 
P/E (TTM) x 62.8 15.0 417.9% View Chart
P/BV x 17.7 2.9 599.5% View Chart
Dividend Yield % 0.0 1.5 -  

Financials

 ASTRAZENECA PHARMA   NATCO PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
NATCO PHARMA
Mar-18
ASTRAZENECA PHARMA/
NATCO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,2781,080 118.3%   
Low Rs883671 131.5%   
Sales per share (Unadj.) Rs228.4592.1 38.6%  
Earnings per share (Unadj.) Rs10.4188.4 5.5%  
Cash flow per share (Unadj.) Rs16.3206.3 7.9%  
Dividends per share (Unadj.) Rs08.25 0.0%  
Dividend yield (eoy) %00.9 0.0%  
Book value per share (Unadj.) Rs98.8833.6 11.8%  
Shares outstanding (eoy) m25.0036.90 67.8%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x4.71.5 319.8%   
Avg P/E ratio x104.24.6 2,242.7%  
P/CF ratio (eoy) x66.44.2 1,565.6%  
Price / Book Value ratio x10.91.1 1,041.2%  
Dividend payout %04.4 0.0%   
Avg Mkt Cap Rs m27,00832,311 83.6%   
No. of employees `0001.44.8 28.1%   
Total wages/salary Rs m1,5353,256 47.2%   
Avg. sales/employee Rs Th4,210.94,522.5 93.1%   
Avg. wages/employee Rs Th1,132.2674.0 168.0%   
Avg. net profit/employee Rs Th191.11,439.0 13.3%   
INCOME DATA
Net Sales Rs m5,71021,848 26.1%  
Other income Rs m123404 30.3%   
Total revenues Rs m5,83322,252 26.2%   
Gross profit Rs m4639,284 5.0%  
Depreciation Rs m147662 22.3%   
Interest Rs m0154 0.0%   
Profit before tax Rs m4388,872 4.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1791,920 9.3%   
Profit after tax Rs m2596,952 3.7%  
Gross profit margin %8.142.5 19.1%  
Effective tax rate %40.821.6 188.7%   
Net profit margin %4.531.8 14.3%  
BALANCE SHEET DATA
Current assets Rs m3,20921,307 15.1%   
Current liabilities Rs m2,0705,920 35.0%   
Net working cap to sales %20.070.4 28.3%  
Current ratio x1.63.6 43.1%  
Inventory Days Days7273 98.8%  
Debtors Days Days35107 32.8%  
Net fixed assets Rs m79014,986 5.3%   
Share capital Rs m50369 13.6%   
"Free" reserves Rs m2,41930,353 8.0%   
Net worth Rs m2,46930,760 8.0%   
Long term debt Rs m00-   
Total assets Rs m4,60537,151 12.4%  
Interest coverage xNM58.6-  
Debt to equity ratio x00-  
Sales to assets ratio x1.20.6 210.8%   
Return on assets %5.619.1 29.4%  
Return on equity %10.522.6 46.4%  
Return on capital %17.729.3 60.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30010,322 2.9%   
Fx outflow Rs m2,0152,978 67.6%   
Net fx Rs m-1,7157,343 -23.4%   
CASH FLOW
From Operations Rs m884,636 1.9%  
From Investments Rs m-94-11,155 0.8%  
From Financial Activity Rs mNA6,509 0.0%  
Net Cashflow Rs m-6-18 31.7%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 75.0 1.5 5,102.0%  
Indian inst/Mut Fund % 0.3 7.8 3.8%  
FIIs % 15.7 16.6 94.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 26.0 35.0%  
Shareholders   12,856 25,395 50.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  ELDER PHARMA  SUVEN LIFESCIENCES  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Falling Stocks, Tumbling Rupee and Weakening Economy(Podcast)

Another week of slowdown in the markets over fears of a looming slowdown in the domestic and global economy continue.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

More Views on News

Most Popular

This 60-Year Old Smallcap Company Could Be Our Next Recommendation(The 5 Minute Wrapup)

Aug 12, 2019

My experience at the recent AGM of this smallcap company which has financials of any FMCG major.

Interest Rates Are Low. Buy Solid Dividend Stocks Instead(The 5 Minute Wrapup)

Aug 13, 2019

The dividends paid by these stocks are helpful when interest rates are falling.

Smallcaps that Will Outperform in the Market Rebound(Profit Hunter)

Aug 12, 2019

Only These Smallcaps Will Give Historic Returns in the Future.

My Top 3 Dividend Stocks to Buy Now(Profit Hunter)

Aug 19, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Chandrayaan 2 Heads to the Moon and It's Good News for These Stocks(The 5 Minute Wrapup)

Aug 14, 2019

Why investors should take note of India's advantage as a low cost satellite launcher...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Aug 23, 2019 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA - GSK PHARMA COMPARISON

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS